drugset / Trial / NCT06470451
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Timeline
- Start
- 2025-01-07
- Primary completion
- 2026-05-22
- Completion
- 2026-05-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hypericin | Other / unclassified | 0.25 % | Topical |